This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Unilateral or bilateral intraocular retinoblastoma
Diagnosis between the ages of 0 - 17.99 years
Diagnosis on or after January 1, 2008
No exclusions based on primary or secondary treatment modalities
None
Retrospective patients (those treated between 2008 and 2018) identified by each site at the start of the study period and prospective patients (those treated between 2018 and 2023) identified at the time of diagnosis by each site during the study period with unilateral or bilateral intraocular retinoblastoma
Case-control
Other
Biospecimen collection
Procedure/SurgeryCollection of tissue and saliva samples
Vision assessment
Other interventionUndergo vision assessment
Questionnaire administration
Other interventionComplete questionnaires
Quality of life assessment
Other interventionComplete questionnaires
Laboratory Biomarker Analysis
Other interventionCorrelative studies
Incidence of acute toxicity
Estimate malignant neoplasm (SMN) risk .Measured through medical record abstraction,
Assess visual outcomes measured via age appropriate visual acuity testing
Assess psycho-social outcomes utilizing questionnaires: BRIEF
Click on the lead sponsor to view all of their trials.
Vanderbilt-Ingram Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
